Want to see IN:ALPA full AI Analyst Report?
Top Page
Alpa Laboratories Limited
(ALPA)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹65.00
▼(-14.02% Downside)
Action:Reiterated
Date:09/06/26
The score is mainly supported by a very strong, low-debt balance sheet and expanding equity base, but is held back by recent operating deterioration and inconsistent revenue/margin trends. Technicals are weak with the stock trading below major moving averages and a negative MACD, and valuation is stretched at a ~37x P/E without a stated dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage gives Alpa financial resilience and reduces the burden of interest and refinancing obligations. This conservative funding structure preserves flexibility to support operations or asset growth while making the business better positioned to withstand periods of weaker profitability.
Negative Factors
Revenue contraction
The latest revenue decline, following uneven growth across prior years, indicates that demand expansion is not yet consistent. For a finished-medicines manufacturer, this weakens visibility into future scale and makes it harder to sustain operating leverage or plan capacity and investment confidently.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage gives Alpa financial resilience and reduces the burden of interest and refinancing obligations. This conservative funding structure preserves flexibility to support operations or asset growth while making the business better positioned to withstand periods of weaker profitability.
Read all positive factors
Alpa Laboratories Limited (ALPA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.30B
Dividend YieldN/A
Average Volume (3M)2.21K
Price to Earnings (P/E)36.7
Beta (1Y)1.65
Revenue Growth0.46%
EPS Growth-83.31%
CountryIN
Employees453
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.68
Shares Outstanding21,040,600
10 Day Avg. Volume1,896
30 Day Avg. Volume2,208
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.52
Price to Sales (P/S)0.92
P/FCF Ratio11.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Alpa Laboratories Limited Business Overview & Revenue Model
Company Description
Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-...
How the Company Makes Money
ALPA makes money primarily by selling pharmaceutical products it manufactures to the market. Revenue is generated from (1) domestic sales of finished medicines to distributors/wholesalers, pharmacies, hospitals, clinics, and other healthcare chann...
Alpa Laboratories Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
86
Very Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.16B | 1.06B | 1.12B | 1.09B | 924.10M | 1.11B |
| Gross Profit | 243.95M | 136.09M | 193.99M | 188.90M | 307.44M | 344.08M |
| EBITDA | 73.81M | 190.47M | 281.01M | 229.96M | 174.43M | 214.31M |
| Net Income | 43.78M | 150.10M | 195.03M | 167.76M | 125.83M | 140.92M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 2.42B | 2.23B | 1.82B | 1.67B | 1.55B |
| Cash, Cash Equivalents and Short-Term Investments | 1.38B | 1.38B | 1.13B | 928.54M | 808.42M | 702.74M |
| Total Debt | 0.00 | 25.08M | 343.00K | 52.47M | 23.04M | 58.47M |
| Total Liabilities | -1.86B | 558.64M | 511.59M | 304.62M | 326.92M | 335.08M |
| Stockholders Equity | 1.86B | 1.86B | 1.71B | 1.52B | 1.35B | 1.22B |
Cash Flow | ||||||
| Free Cash Flow | 89.97M | 84.84M | -21.42M | -27.36M | 77.78M | 77.49M |
| Operating Cash Flow | 106.65M | 124.37M | 92.37M | 36.49M | 89.04M | 99.40M |
| Investing Cash Flow | -144.58M | -143.01M | -35.13M | -133.36M | 21.27M | -156.10M |
| Financing Cash Flow | 22.40M | 24.80M | -52.47M | 25.83M | -37.93M | 54.42M |
Alpa Laboratories Limited Technical Analysis
Negative
75.60
Price Trends
65.78
Negative
67.35
Negative
68.73
Negative
Market Momentum
-0.79
Negative
43.54
Neutral
35.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALPA, the sentiment is Negative. The current price of 75.6 is above the 20-day moving average (MA) of 62.67, above the 50-day MA of 65.78, and above the 200-day MA of 68.73, indicating a bearish trend. The MACD of -0.79 indicates Negative momentum. The RSI at 43.54 is Neutral, neither overbought nor oversold. The STOCH value of 35.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALPA.
Alpa Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.73B | 11.96 | ― | 0.70% | 4.29% | 2.40% | |
60 Neutral | ₹1.95B | 14.63 | ― | ― | -7.71% | 927.75% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.30B | 36.72 | ― | ― | 0.46% | -83.31% | |
49 Neutral | ₹1.71B | 23.66 | ― | 1.12% | 13.51% | -14.80% | |
48 Neutral | ₹2.23B | -1.01 | ― | 20.72% | -99.53% | -41.93% | |
47 Neutral | ₹561.12M | 116.33 | ― | ― | 9.31% | -82.71% |
* General Sector Average
IN:ALPA
Alpa Laboratories Limited
61.85
-32.64
-34.54%
IN:BALPHARMA
Bal Pharma Limited
107.47
20.92
24.17%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
34.48
-9.02
-20.74%
IN:BROOKS
Brooks Laboratories Limited
66.25
-91.80
-58.08%
IN:NECLIFE
Nectar Lifesciences Ltd.
11.50
-5.04
-30.47%
IN:PAR
Par Drugs and Chemicals Limited
140.92
35.15
33.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.